Scarica l'app Stockscreener
8.23
1.79%
-0.15
Dopo l'orario di chiusura:
8.23
Precedente Chiudi:
$8.38
Aprire:
$8.22
Volume 24 ore:
880.27K
Relative Volume:
0.94
Capitalizzazione di mercato:
$425.03M
Reddito:
$742.90M
Utile/perdita netta:
$52.60M
Rapporto P/E:
9.9216
EPS:
0.8295
Flusso di cassa netto:
$156.80M
1 W Prestazione:
+1.86%
1M Prestazione:
-8.45%
6M Prestazione:
-10.45%
1 anno Prestazione:
+59.19%
Intervallo 1D:
$8.065
$8.36
Intervallo di 1 settimana:
$7.90
$8.54
Portata 52W:
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.23 | 425.03M | 742.90M | 52.60M | 156.80M | 0.8295 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Iniziato | The Benchmark Company | Buy |
| 2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
| 2018-06-13 | Iniziato | Argus | Buy |
| 2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Singular Research | Buy |
| 2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
| 2016-03-28 | Iniziato | Singular Research | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2014-05-15 | Iniziato | Summer Street Research | Buy |
| 2011-05-31 | Reiterato | WBB Securities | Strong Buy |
| 2011-01-10 | Reiterato | Wedbush | Outperform |
| 2010-11-05 | Reiterato | Wedbush | Outperform |
| 2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
EBS PE Ratio & Valuation, Is EBS Overvalued - Intellectia AI
Emergent BioSolutions Inc. (EBS) stock price, news, quote and history - Yahoo Finance UK
Emergent BioSolutions Inc. (EBS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Emergent BioSolutions Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Insider Sell: Paul Williams Sells 4,000 Shares of Emergent BioSo - GuruFocus
Emergent BioSolutions (NYSE: EBS) SVP sells 4,000 shares - Stock Titan
Emergent Biosolutions directs 2026 Cycle A donations to public health and scientific outreach - Traders Union
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences - bitget.com
[144] Emergent BioSolutions Inc. SEC Filing - Stock Titan
Chart Watch: Is Emergent BioSolutions Inc stock forming a triangle patternEarnings Performance Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Emergent BioSolutions (EBS) price target decreased by 11.11% to 12.24 - MSN
Risks Report: Is Emergent BioSolutions Inc stock showing strong momentumShort Setup & Weekly Sector Rotation Insights - baoquankhu1.vn
Emergent BioSolutions Inc. (EBS) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Vanguard disaggregates holdings; reports zero Emergent BioSolutions stake (NYSE: EBS) - Stock Titan
Decliners Report: Can Emergent BioSolutions Inc grow without external fundingQuarterly Profit Report & Accurate Intraday Trading Signals - baoquankhu1.vn
H.C. Wainwright reiterates Emergent BioSolutions stock rating on contract wins - au.investing.com
H.C. Wainwright reiterates Emergent BioSolutions stock rating on contract wins By Investing.com - Investing.com South Africa
Emergent BioSolutions secures $60.6M in smallpox contracts By Investing.com - au.investing.com
Emergent BioSolutions secures $60M contracts - MSN
Emergent Biosolutions stock rises on $54M government contract By Investing.com - Investing.com Canada
How The Reset Price Target Is Shaping The Emergent BioSolutions (EBS) Investment Story - finance.yahoo.com
Emergent Biosolutions stock rises on $54M government contract - Investing.com
Emergent BioSolutions (EBS) Secures $54M Smallpox Preparedness C - GuruFocus
Emergent BioSolutions Gets $54 Million Contract Award for Smallpox Preparedness - marketscreener.com
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures - Bitget
Emergent BioSolutions secures $60.6M in smallpox contracts - Investing.com
Q&A: Emergent BioSolutions Lands $60M+ in Smallpox Preparedness Deals — What’s the Impact? - citybiz
Emergent Biosolutions wins fresh U.S. government agreement and boosts international orders - Traders Union
Emergent Biosolutions introduces new NARCAN Nasal Spray carrying cases to support overdose response - Traders Union
Emergent BioSolutions authorizes $50 million stock repurchase program - MSN
Smart Money: Can Emergent BioSolutions Inc stock outperform in a bear marketTake Profit & Daily Chart Pattern Signals - baoquankhu1.vn
Emergent BioSolutions (NYSE: EBS) details 2026 votes on board, pay and stock plan - Stock Titan
Emergent BioSolutions signs contract modification award for CNJ-016 - MSN
U.S. Smallpox Treatment Market: See Incredible Growth - openPR.com
Mpox Is on the Rise in the U.S. 3 Vaccine Stocks Worth a Second Look. - Barron's
Emergent BioSolutions outlines $720M–$760M 2026 revenue target as transformation plan advances - MSN
EBS Stock Price, Quote & Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
How The Investment Narrative For Emergent BioSolutions (EBS) Is Shifting After The $12 Target Reset - Yahoo Finance
BioThrax (Emergent BioSolutions) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F - Yahoo Finance
H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue miss - Investing.com Nigeria
HC Wainwright Lowers Emergent Biosolutions (NYSE:EBS) Price Target to $12.00 - MarketBeat
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):